Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA) ; volume:10 ; number:1 ; day:23 ; month:11 ; year:2012 ; pages:1-10 ; date:12.2012
Pediatric rheumatology ; 10, Heft 1 (23.11.2012), 1-10, 12.2012
- Urheber
-
Kumar, Sharath
Kunhiraman, Divya Shree
Rajam, Lalitha
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-10-40
- URN
-
urn:nbn:de:101:1-2019080200583076526965
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kumar, Sharath
- Kunhiraman, Divya Shree
- Rajam, Lalitha
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Quality improvement in juvenile idiopathic arthritis: a mixed-methods implementation pilot of the CAPTURE-JIA dataset
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Quality improvement in juvenile idiopathic arthritis: a mixed-methods implementation pilot of the CAPTURE-JIA dataset
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
Medication therapy patients with juvenile idiopathic arthritis (JIA), who needed joint replacement in adult life
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)